Abstract:Background: Continuous understanding of the epidemiology of drug resistant TB, especially for multidrug/extensively drug resistant TB (MDR/XDR-TB) is essential to develop the appropriate strategies for preventing its epidemic. The present study aimed to investigate the longitudinal trend of the rates and dynamic change of MDR/XDR M.Tuberculosis and its transmission pattern to adjust the TB control activities in eastern rural China. Methods: The data presented here spanned 8 years and was derived from three population-based studies of drug-resistant TB in two eastern rural counties: DQ and GY in terms of socio-demographic characteristics of drug-resistant cases, as well as the microbiological and molecular features of their infected M. Tuberculosis strains in eastern rural China. Results: Of the 990 smear-positive patients within the studied period, 413 (41.7%) cases showed resistance to any of the detected first- (INH, RIF and EMB) and second-line (OFL, LEV, KAN, AMK, and CAP) anti-TB drugs: 89 with MDR (9.0%). Of these MDR-TB isolates, 34 cases (38.2%) showed resistance to any of the second-line anti-TB drugs: 25 (28.1%) with resistance either to FQs or second-line injective drugs (Pre-XDR) and 9 (10.1%) showed simultaneous resistance to the two categories (XDR). Molecular analysis of pncA gene revealed 185 M. Tuberculosis cases contained the mutation associated with PZA resistance, with a significantly higher proportion in MDR compared with the others (35% vs. 16.8%, p = 0.04). For the longitudinal perspective, MDR-TB (from 9.1% to 14.5%, p = 0.001), Pre-XDR-TB (from 2.5% to 4.5%, p = 0.01) and XDR-TB (from 0.9% to 3.6%, p = 0.04) exhibited an upward trend, while there was a significant decreasing change in the proportion of totally first-line drug sensitivity (p = 0.047). Non-linear regression analysis showed that MDR-TB, Pre-XDR-TB and XDR-TB increased significantly over the study period with a double time of 4.8 year (95% CI: 3.69–5.92), 3.2 year (95% CI: 2.16–5.94) and 3.3 year (95% CI: 1.099–8.32). Being clustered, sputum smear result and previously treated history were factors increasing the trending of M/XDR-TB. The MIRU24 loci genotyping revealed the 21 clusters involving 48 (28.4%) drug-resistant cases in DQ and 28 clusters involving 59 (32.1%) drug-resistant cases in GY. Of these clusters, 11 were related to MDR/XDR-TB and 8 of these clustered genotypes were observed more than 5 years of the study period. Conclusion: These results show that active transmission of MDR/XDR-TB is taking place and that the increasing trend in the observed rate of MDR/XDR-TB tends to be due to the variation in the distribution of patients with different socio-demographic features and the continued transmission of particular genetic clusters. Continuous surveillance of clinical isolates of M. Tuberculosis is needed to identify M/XDR-TB, especially in patients who have a history of TB and have received prior anti-TB treatment.

The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

Extensively Drug-Resistant Tuberculosis in Sub-Saharan Africa: an Emerging Public-Health Concern

Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022

Evidence-based Definition for Extensively Drug-Resistant Tuberculosis

Advances in research of extensively drug-resistant tuberculosis

Drug resistant TB - latest developments in epidemiology, diagnostics and management

Clinical and operational value of the extensively drug-resistant tuberculosis definition

New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition

Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice?

The past, present and future of tuberculosis treatment.

Drug-Resistant Tuberculosis Types and Their Treatment Regimens Using First-Line, Second-Line Injectable, Third-Line, Fluoroquinolones, Aminoglycosides, Cyclic Polypeptides, Novel and Repurposed Anti-Tuberculosis Drugs

Pre-extensively drug-resistant and extensively drug-resistant tuberculosis in Latin America and the Caribbean: A systematic review and meta-analysis

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

The longitudinal trends of multidrug and extensively drug resistant tuberculosis in China

Multi-drug resistant tuberculosis burden and risk factors: an update

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape

Drug-resistant tuberculosis: a persistent global health concern

25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward

Polymerase Chain Reaction (PCR) Profiling of Extensively Drug-Resistant (XDR) Pathogenic Bacteria in Pulmonary Tuberculosis Patients